Nan Fung Trinity HK Ltd. Makes New $7.82 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Nan Fung Trinity HK Ltd. purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 938,200 shares of the biotechnology company’s stock, valued at approximately $7,815,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Fifth Third Bancorp boosted its stake in BioCryst Pharmaceuticals by 12.5% in the 3rd quarter. Fifth Third Bancorp now owns 134,967 shares of the biotechnology company’s stock worth $1,124,000 after purchasing an additional 15,025 shares in the last quarter. Winthrop Capital Management LLC bought a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at about $25,000. Allspring Global Investments Holdings LLC bought a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at about $431,000. Ethic Inc. increased its stake in BioCryst Pharmaceuticals by 180.6% during the 3rd quarter. Ethic Inc. now owns 34,482 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 22,193 shares in the last quarter. Finally, Alps Advisors Inc. raised its holdings in BioCryst Pharmaceuticals by 6.5% in the third quarter. Alps Advisors Inc. now owns 338,545 shares of the biotechnology company’s stock worth $2,820,000 after buying an additional 20,585 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $7.68 on Friday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.23 and a one year high of $11.22. The business’s fifty day moving average is $8.28 and its 200 day moving average is $8.77. The stock has a market capitalization of $1.98 billion, a PE ratio of -5.41 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative return on equity of 92.91% and a negative net margin of 37.40%. The business had revenue of $180.29 million during the quarter, compared to analyst estimates of $165.67 million. During the same quarter in the previous year, the firm earned $0.06 EPS. BioCryst Pharmaceuticals’s revenue was up 13.1% on a year-over-year basis. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the topic of several analyst reports. Royal Bank Of Canada downgraded shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $13.00 to $11.00 in a research note on Thursday, September 10th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. JPMorgan Chase & Co. raised their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Wednesday, September 30th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, Weiss Ratings downgraded BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.38.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.